|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002598,
umls-concept:C0008976,
umls-concept:C0021102,
umls-concept:C0030705,
umls-concept:C0033972,
umls-concept:C0034656,
umls-concept:C0035171,
umls-concept:C0042514,
umls-concept:C0162589,
umls-concept:C0180307,
umls-concept:C0232197,
umls-concept:C0870733,
umls-concept:C1261322,
umls-concept:C1518601,
umls-concept:C1550456,
umls-concept:C1556094
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-2-27
|
|
pubmed:abstractText |
Implantable cardioverter-defibrillators (ICDs) are the most effective therapy in reducing the mortality of patients with life-threatening ventricular tachyarrhythmias. However, the ICD cannot prevent the recurrence of tachycarida attacks and that limits the clinical usefulness of them. The Nippon ICD Plus Pharmachologic Option Necessity (NIPPON) trial was designed as the first prospective randomized study to test the hypothesis whether amiodarone could improve the patient's clinical outcome by reducing the amount of ICD therapy in the Japanese patient population.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1346-9843
|
|
pubmed:author |
pubmed-author:(Nippon ICD Plus Pharmachologic Option Necessity (NIPPON) Investigators),
pubmed-author:AizawaYoshifusaY,
pubmed-author:AonumaKazutakaK,
pubmed-author:ChinushiMasaomiM,
pubmed-author:FurushimaHiroshiH,
pubmed-author:KobayashiYoshinoriY,
pubmed-author:KodamaItsuoI,
pubmed-author:KuritaTakashiT,
pubmed-author:MitamuraHideoH,
pubmed-author:NittaTakashiT,
pubmed-author:OgawaSatoshiS,
pubmed-author:OheTohruT,
pubmed-author:OhtsuHiroshiH,
pubmed-author:SatomiKazuhiroK,
pubmed-author:SoejimaKyokoK,
pubmed-author:TsuboiNaoyaN,
pubmed-author:YamazakiTsutomuT
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
70
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
316-20
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16501299-Amiodarone,
pubmed-meshheading:16501299-Anti-Arrhythmia Agents,
pubmed-meshheading:16501299-Combined Modality Therapy,
pubmed-meshheading:16501299-Defibrillators, Implantable,
pubmed-meshheading:16501299-Follow-Up Studies,
pubmed-meshheading:16501299-Humans,
pubmed-meshheading:16501299-Incidence,
pubmed-meshheading:16501299-Japan,
pubmed-meshheading:16501299-Prospective Studies,
pubmed-meshheading:16501299-Recurrence,
pubmed-meshheading:16501299-Research Design,
pubmed-meshheading:16501299-Tachycardia, Ventricular,
pubmed-meshheading:16501299-Treatment Outcome,
pubmed-meshheading:16501299-Ventricular Fibrillation
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Japanese randomized trial for investigation of a combined therapy of amiodarone and implantable cardioverter defibrillator in patients with ventricular tachycardia and fibrillation: the Nippon ICD Plus Pharmachologic Option Necessity study design.
|
|
pubmed:affiliation |
Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Japan. kuritat@hsp.ncvc.go.jp
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
